Disease · MONDO_0005578
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Adult Participants vs Pediatric Participants: Serious Infectious Event | 114 of 581 | 8 of 58 | 639 | NCT00357903 | Trial comparisons |
| Adult Participants vs Pediatric Participants: Lymphoma | 6 of 581 | 0 of 58 | 639 | NCT00357903 | Trial comparisons |
| Adult Participants vs Pediatric Participants: Death | 23 of 581 | 0 of 58 | 639 | NCT00357903 | Trial comparisons |
| Adult Participants vs Pediatric Participants: Malignancy | 48 of 581 | 0 of 58 | 639 | NCT00357903 | Trial comparisons |
| Total Adults vs Pediatric Subjects: serious adverse events | 293 of 581 | 16 of 58 | 639 | NCT00357903 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: deaths from any cause | 0 of 95 | 0 of 48 | 143 | NCT02728752 | Trial comparisons |
| Overall Period Octagam vs First Period Placebo: serious adverse events | 14 of 95 | 2 of 48 | 143 | NCT02728752 | Trial comparisons |
| Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS) | 37 of 47 | 21 of 48 | 95 | NCT02728752 | Trial comparisons |
| Nitisinone-treated vs Control: serious adverse events | 6 of 20 | 0 of 20 | 40 | NCT00107783 | Trial comparisons |
| CBD Group vs Shea Butter Group: Rate of Side Effects Using Novel CBD Cream. | 0 of 18 | 0 of 18 | 36 | NCT04611347 | Trial comparisons |
| CBD Intervention vs Shea Butter Intervention: deaths from any cause | 0 of 18 | 0 of 18 | 36 | NCT04611347 | Trial comparisons |
| CBD Intervention vs Shea Butter Intervention: serious adverse events | 0 of 18 | 0 of 18 | 36 | NCT04611347 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005578/comparisons